HC Wainwright Predicts Lower Earnings for Trevi Therapeutics

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities researchers at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Trevi Therapeutics in a research note issued on Wednesday, December 4th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings of ($0.49) per share for the year, down from their prior estimate of ($0.47). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q1 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at ($0.38) EPS.

Other analysts have also recently issued research reports about the stock. D. Boral Capital reiterated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, December 4th. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. Leerink Partnrs upgraded Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. B. Riley reiterated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a research report on Monday, October 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, December 4th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $9.13.

Trevi Therapeutics Trading Up 6.2 %

Trevi Therapeutics stock opened at $2.76 on Monday. Trevi Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.00. The company has a market cap of $212.16 million, a PE ratio of -6.27 and a beta of 0.96. The company’s 50-day moving average is $2.99 and its two-hundred day moving average is $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same period in the previous year, the business earned ($0.08) earnings per share.

Institutional Trading of Trevi Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after buying an additional 60,249 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new stake in Trevi Therapeutics in the 1st quarter valued at $47,000. Bank of New York Mellon Corp boosted its position in Trevi Therapeutics by 38.8% during the second quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock worth $532,000 after purchasing an additional 49,884 shares during the period. Rhumbline Advisers grew its stake in Trevi Therapeutics by 44.8% in the 2nd quarter. Rhumbline Advisers now owns 75,218 shares of the company’s stock valued at $224,000 after buying an additional 23,263 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in Trevi Therapeutics by 17.1% during the second quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after acquiring an additional 7,902 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.